Literature DB >> 1516760

Long-term suppression of postprandial hyperglycaemia with acarbose retards the development of neuropathies in the BB/W-rat.

A A Sima1, S Chakrabarti.   

Abstract

The effect of the alpha-glucosidase inhibitor acarbose on postprandial hyperglycaemia was explored in the spontaneously diabetic BB/W-rat. Acarbose-treatment (5 mg.kg body weight-1.day-1) of diabetic BB/W-rats maintained on small doses of insulin, was associated with a 40% reduction in the 24-h glucose area compared to non-treated diabetic rats. Over a 4 month treatment period this reduction in cumulative hyperglycaemia resulted in a complete prevention of autonomic polyneuropathy as indicated by R-BAR values. The development of somatic polyneuropathy in the BB/W-rat was significantly attenuated by acarbose treatment with a partial prevention of the characteristic nerve conduction velocity slowing during the first 3 months of diabetes, but no longer at 4 months. Characteristic structural abnormalities associated with diabetes in this model, such as axonal atrophy and axo-glial dysjunction, were significantly but only partially prevented in rats treated with acarbose for a diabetes duration of 4 months. These data suggest that postprandial lowering of hyperglycaemia resulting in a decrease in cumulative hyperglycaemia retards the development of diabetic polyneuropathies in the BB/W-rat.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516760     DOI: 10.1007/bf00401199

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  28 in total

1.  [Diabetic neuropathy. Pathologic anatomy, pathophysiology and pathogenesis on the basis of electron microscopic studies].

Authors:  A Bischoff
Journal:  Dtsch Med Wochenschr       Date:  1968-02-09       Impact factor: 0.628

2.  Axo-glial dysjunction. A novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic bio-breeding rat.

Authors:  A A Sima; S A Lattimer; S Yagihashi; D A Greene
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

3.  Effects of an alpha-glucosidase inhibitor, acarbose, on blood glucose and serum lipids in streptozotocin-induced diabetic rats.

Authors:  K Yamashita; S Sugawara; I Sakairi
Journal:  Horm Metab Res       Date:  1984-04       Impact factor: 2.936

4.  Endoneurial microvessels in human diabetic neuropathy. Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor.

Authors:  A A Sima; V Nathaniel; A Prashar; V Bril; D A Greene
Journal:  Diabetes       Date:  1991-09       Impact factor: 9.461

5.  The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man.

Authors:  I Hillebrand; K Boehme; K H Graefe; K Wehling
Journal:  Klin Wochenschr       Date:  1986-04-15

6.  Autonomic neuropathy in BB rat. Assessment by improved method for measuring heart-rate variability.

Authors:  T A McEwen; A A Sima
Journal:  Diabetes       Date:  1987-03       Impact factor: 9.461

7.  Axonal atrophy in sensory nerves of the diabetic BB-Wistar rat: a possible early correlate of human diabetic neuropathy.

Authors:  A A Sima; M Bouchier; H Christensen
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

8.  Effects of graded alpha-glucosidase inhibition on sugar absorption in vivo.

Authors:  H Madariaga; P C Lee; L A Heitlinger; E Lebenthal
Journal:  Dig Dis Sci       Date:  1988-08       Impact factor: 3.199

9.  Ultrastructural pathology of peripheral nerves in patients with diabetic neuropathy.

Authors:  S Yagihashi; M Matsunaga
Journal:  Tohoku J Exp Med       Date:  1979-12       Impact factor: 1.848

10.  Reversible and irreversible nodal dysfunction in diabetic neuropathy.

Authors:  T Brismar; A A Sima; D A Greene
Journal:  Ann Neurol       Date:  1987-05       Impact factor: 10.422

View more
  8 in total

Review 1.  Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.

Authors:  R Rabasa-Lhoret; J L Chiasson
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 3.923

Review 2.  Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

Authors:  B H Wolffenbuttel; T W van Haeften
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

3.  Cinnamon extract inhibits α-glucosidase activity and dampens postprandial glucose excursion in diabetic rats.

Authors:  H Mohamed Sham Shihabudeen; D Hansi Priscilla; Kavitha Thirumurugan
Journal:  Nutr Metab (Lond)       Date:  2011-06-29       Impact factor: 4.169

4.  Microencapsulation and the Characterization of Polyherbal Formulation (PHF) Rich in Natural Polyphenolic Compounds.

Authors:  Syed Ammar Hussain; Ahsan Hameed; Yusuf Nazir; Tahira Naz; Yang Wu; Hafiz Ansar Rasul Suleria; Yuanda Song
Journal:  Nutrients       Date:  2018-06-28       Impact factor: 5.717

5.  In Vitro Antidiabetic Effects of Isolated Triterpene Glycoside Fraction from Gymnema sylvestre.

Authors:  Rashmi S Shenoy; K V Harish Prashanth; H K Manonmani
Journal:  Evid Based Complement Alternat Med       Date:  2018-08-08       Impact factor: 2.629

6.  In vitro α -amylase and α-glucosidase inhibitory potential of Trigonella foenum-graecum leaves extract.

Authors:  Aditya Ganeshpurkar; Varsha Diwedi; Yash Bhardwaj
Journal:  Ayu       Date:  2013-01

7.  Evaluation of α-Glucosidase Inhibitory Effect of 50% Ethanolic Standardized Extract of Orthosiphon stamineus Benth in Normal and Streptozotocin-Induced Diabetic Rats.

Authors:  Elsnoussi Ali Mohamed; Mariam Ahmad; Lee Fung Ang; Mohd Zaini Asmawi; Mun Fei Yam
Journal:  Evid Based Complement Alternat Med       Date:  2015-11-16       Impact factor: 2.629

8.  Postprandial anti-hyperglycemic activity of marine Streptomyces coelicoflavus SRBVIT13 mediated gold nanoparticles in streptozotocin induced diabetic male albino Wister rats.

Authors:  Sathyanarayanan Ravi Sathish Kumar; Kokati Venkata Bhaskara Rao
Journal:  IET Nanobiotechnol       Date:  2016-10       Impact factor: 1.847

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.